Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.

Moore-Carrasco R, Busquets S, Almendro V, Palanki M, López-Soriano FJ, Argilés JM. The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol. 2007 May; 30(5):1239-45.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.